| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S17121 R71679 |
Van der Zande - Diuretics, 2024 | Small for gestational age (birth weight <10th percentile) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: Yes Indications Antihypertensive: Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) | 1.35 [0.97;1.89] | 57/382 527/5,357 | 584 | 382 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13924 R54508 |
Fisher b - Diuretics (Controls unexposed, disease free), 2018 | Small for gestational age (birthweight < 10th percentile for a given gestational age in weeks, sex, race/ethnicity, and parity) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, disease free excluded | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified |
2.47 [0.45;9.18] excluded (control group) |
3/15 923/10,050 | 926 | 15 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13925 R54509 |
Fisher b - Diuretics (Controls unexposed, sick), 2018 | Small for gestational age (birthweight < 10th percentile for a given gestational age in weeks, sex, race/ethnicity, and parity) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified | 1.83 [0.51;6.58] C | 3/15 101/839 | 104 | 15 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13447 R51806 |
Su - Diuretics (Controls unexposed, disease free), 2013 | Small for gestational age (<10th percentile for gestational age and gender) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication |
1.11 [0.84;1.47] C excluded (control group) |
62/371 1,250/8,181 | 1,312 | 371 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18078 R76128 |
Su - Diuretics (Controls unexposed, sick), 2013 | Small for gestational age (<10th percentile for gestational age and gender) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes Indications Antihypertensive: Only chronic hypertension indication | 0.89 [0.65;1.22] | 62/371 184/1,006 | 246 | 371 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13473 R51970 |
Nakhai-Pour - Diuretics, 2010 | Small for gestational age (a birth weight less than the 10th percentile for that gestational age and gender) | 2nd and/or 3rd trimester | nested case control | unexposed (general population or NOS) | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified | 1.88 [0.39;9.03] C | 2/9 7,443/56,325 | 7,445 | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13514 R52204 |
Mabie - Hydrochlorothiazide, 1986 | Intra-uterine growth retardation (birthweight < 10th percentile according to Lubchenco curve) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication | 2.17 [0.22;21.55] C | 1/10 4/82 | 5 | 10 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 5 studies | 1.14 [0.87;1.48] | 8,384 | 787 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick; 2: Controls unexposed, sick;
Asymetry test p-value = 0.3205 (by Egger's regression)
slope=-0.0673 (0.1904); intercept=0.8924 (0.7516); t=1.1874; p=0.3205
excluded 13447, 13924